The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Patient-reported outcomes (PROs) comparison of 5-FU and capecitabine (cape) with concurrent radiotherapy (RT) for neoadjuvant treatment of rectal cancer: Results of NSABP R-04.
Greg Yothers
No relevant relationships to disclose
Patricia A. Ganz
No relevant relationships to disclose
Samia H. Lopa
No relevant relationships to disclose
Clifford Y. Ko
No relevant relationships to disclose
D. Lawrence Wickerham
No relevant relationships to disclose
Norman Wolmark
Consultant or Advisory Role - Sanofi (U)